Respiratory research

Respiratory and thoracic oncology research at St John of God Health Care is concerned with improving outcomes for patients with a broad spectrum of respiratory diseases and disorders. We work in collaboration with the schools of medicine at the University of Notre Dame and University of Western Australia and coordinate multicenter studies in WA, Australia and internationally.

St John of God Subiaco Hospital respiratory and lung oncology research has been made possible by a generous donation from the Bendat Family.

  • Respiratory diseases including lung cancer are very common in Australia. Lung cancer itself is the fourth most commonly diagnosed cancer and the most common cause of cancer-related death in both men and women.
  • Respiratory diseases and disorders have a range of negative outcomes for those affected, with their quality of life reduced and an increased risk of hospitalisation.
  • Our research aims to improve patients’ lives and ensure they are confident to manage their condition and have a better quality of life.
  • Our research focuses on lung cancer, pulmonary hypertension (high blood pressure), respiratory complications of connective tissue disorders and respiratory issues in bariatric surgery.
  • We are also beginning to expand our research into pleural disease, scaroidosis and pneumonia – which affects the very young and very old.
Lead Investigator
Professor Eli Gabbay

Oncologists
Dr Timothy Clay
Dr Andrew Dean

Intensivist
Dr David Morgan

Junior doctor
Dr Megan Harrison

Medical honours student
Adam Trytell

Research nurse
Tara Hannon

Casamento K, Laverty A, Wilsher M, Twiss J, Gabbay E, Glaspole I, Jaffe A.  Assessing the feasibility of a web-based registry for multiple orphan lung diseases: the Australasian Registry Network for Orphan Lung Disease (ARNOLD) experience.  Orphanet J Rare Dis. 2016 Apr 18;11:42. doi: 10.1186/s13023-016-0389-z PMID:27090393

Gabbay E, Slotki I, Shavit L. Weighing the evidence: obesity, metabolic syndrome, and the risk of chronic kidney disease. BMC Nephrol. 2015 Aug 7; 16:133. doi: 10.1186/s12882-015-0137-y. PMID: 26249332

Moore O, Proudman S, Goh N, Corte T, Rouse H, Hennesey O, Morrisroe K, Thakkar V, Sahhar J, Roddy J, Yousef P, Gabbay E, Nash P, Zochling J, Stevens W, Nikpour N. Quantifying change in Pulmonary Function as a Prognostic Marker in Systemic Sclerosis Related Interstitial Lung Disease. Clinical and Experimental Rheumatology 2015;33:S111-S116

Quinlivan A, Thakkar V, Stevens W, Morrisroe K, Prior D, Rabusa C, Youssef P, Gabbay E, Roddy J, Walker JG, Zochling J, Sahhar J, Nash P, Lester S, Rischmueller M, Proudman SM, Nikpour M. Cost Savings with a New Screening Algorithm for Pulmonary Arterial Hypertensionin Systemic Sclerosis. Internal Medicine Journal 2015; 45:1134-1140.

 Richardson MM, Paine SS, Grobert ME, Stidley CA, Gabbay E, Harford AM, Zager PG, Miskulin DC, Meyer KB  Satisfaction with Care of Patients on Hemodialysis. Clin J Am Soc Nephrol. 2015 Aug 7;10(8):1428-34. doi: 10.2215/CJN.11241114. Epub 2015 Jun 30.PMID:2613061 

Thakkar V, Stevens W, Prior D, Rabusa C, Sahhar J, Walker JG, Roddy J, Lester S, Rischmueller M, Zochling J, Nash P, Gabbay E, Youssef P, Proudman SM, Nikpour M. The role of asymmetric dimethylarginine alone and in combination with N-terminal pro-B-type natriuretic peptide as a screening biomarker for systemic sclerosis-related pulmonary arterial hypertension: a case control study. Clin Exp Rheumatol. 2016 May 23. [Epub ahead of print] PMID: 27214686 

Yanjie H, Thakkar V, Stevens W, Morrisroe K, Prior D, Rabusa C, Yousef P, Gabbay E, Roddy J, Walker J, Zochling J, Sahhar J, Nash P, Lester S, Rischmueller M, Proudman SM, Nikpour N. A Comparison of the Predictive Accuracy of Three Screening Models for Pulmonary Arterial Hypertension in Systemic Sclerosis. Arthritis Research and Therapy 2016 in press.